RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0038-1636540
Procoagulant State in Current and Former Anabolic Androgenic Steroid Abusers
Funding J.J. Rasmussen and C. Kistorp received unrestricted research grants from Antidoping Denmark (grant number: N/A), J.J. Rasmussen received a faculty scholarship from the University of Copenhagen (grant number: N/A). The work was further funded by grants from Research Foundation of Herlev Hospital (grant number: N/A) and The Danish Heart Foundation (grant number: 15-R99-A5797-22952).
Publikationsverlauf
13. Oktober 2017
05. Januar 2018
Publikationsdatum:
04. April 2018 (online)
Abstract
Background Anabolic androgenic steroid (AAS) abusers are considered at increased risk of cardiovascular morbidity and mortality. We hypothesized that current and former AAS abuse would induce a procoagulant shift in the haemostatic balance.
Methods Men 18 to 50 years of age were included as current AAS abusers, former AAS abusers or controls. Morning blood samples were collected after overnight fasting. Thrombin generation (lag time, time to peak, peak height, and endogenous thrombin potential [ETP]) and coagulation factor II (prothrombin), VII and X, antithrombin, protein C, free protein S and tissue factor pathway inhibitor (TFPI) were assessed. Groups were compared by ANOVA or Kruskal–Wallis test and probabilities were corrected for multiple comparisons. Associations were evaluated using linear regression models.
Results ETP was increased around 15% in current (n = 37) and former (n = 33) AAS abusers compared with controls (n = 30; p < 0.001). Prothrombin and factor X were increased ≥10% in AAS abusers and prothrombin was a predictor of ETP (p < 0.0005). Lag time and time to peak were increased 10 to 30% in current AAS abusers (p < 0.001) and associated with higher concentrations of TFPI, antithrombin, protein C and protein S (p < 0.0005; = 0.005). Multivariate linear regression, with all coagulation inhibitors as covariates, identified TFPI to be independently associated with lag time and time to peak (p < 0.0005).
Conclusion Thrombin generation is augmented in current and former AAS abusers, reflecting a procoagulant state, with altered concentrations of coagulation proteins. Prospective studies are needed to clarify whether these findings translate into an increased thrombotic risk in AAS abusers potentially even after cessation.
* Simon Chang and Jon J Rasmussen contributed equally to this study.
-
References
- 1 Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol 2014; 24 (05) 383-398
- 2 Pope Jr HG, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. Am J Addict 2014; 23 (04) 371-377
- 3 Baggish AL, Weiner RB, Kanayama G. , et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation 2017; 135 (21) 1991-2002
- 4 Angell P, Chester N, Green D, Somauroo J, Whyte G, George K. Anabolic steroids and cardiovascular risk. Sports Med 2012; 42 (02) 119-134
- 5 La Gerche A, Brosnan MJ. Cardiovascular effects of performance-enhancing drugs. Circulation 2017; 135 (01) 89-99
- 6 Lippi G, Banfi G. Doping and thrombosis in sports. Semin Thromb Hemost 2011; 37 (08) 918-928
- 7 Thiblin I, Garmo H, Garle M. , et al. Anabolic steroids and cardiovascular risk: a national population-based cohort study. Drug Alcohol Depend 2015; 152: 87-92
- 8 Ansell JE, Tiarks C, Fairchild VK. Coagulation abnormalities associated with the use of anabolic steroids. Am Heart J 1993; 125 (2, Pt 1): 367-371
- 9 Kluft C, Preston FE, Malia RG. , et al. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemost 1984; 51 (02) 157-164
- 10 Kahn NN, Sinha AK, Spungen AM, Bauman WA. Effects of oxandrolone, an anabolic steroid, on hemostasis. Am J Hematol 2006; 81 (02) 95-100
- 11 Walker ID, Davidson JF, Young P, Conkie JA. Effect of anabolic steroids on plasma antithrombin III: alpha2 macroglobulin and alpha1 antitrypsin levels. Thromb Diath Haemorrh 1975; 34 (01) 106-114
- 12 Thorisdottir H, Evans JA, Schwartz HJ, Comp P, Haluschak J, Ratnoff OD. Some clotting factors in plasma during danazol therapy: free and total protein S, but not C4b-binding protein, are elevated by danazol therapy. J Lab Clin Med 1992; 119 (06) 698-701
- 13 Lowe GD, Thomson JE, Reavey MM, Forbes CD, Prentice CR. Mesterolone: thrombosis during treatment, and a study of its prothrombotic effects. Br J Clin Pharmacol 1979; 7 (01) 107-109
- 14 Vanberg P, Atar D. Androgenic anabolic steroid abuse and the cardiovascular system. Handb Exp Pharmacol 2010; (195) 411-457
- 15 Ferenchick GS, Hirokawa S, Mammen EF, Schwartz KA. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol 1995; 49 (04) 282-288
- 16 Al Dieri R, de Laat B, Hemker HC. Thrombin generation: what have we learned?. Blood Rev 2012; 26 (05) 197-203
- 17 Ten Cate H, Hemker HC. Thrombin generation and atherothrombosis: what does the evidence indicate?. J Am Heart Assoc 2016; 5 (08) e003553
- 18 Aziz M, Sidelmann JJ, Wissing ML, Faber J, Skouby SO. Endogenous thrombin potential in polycystic ovary syndrome: the association to body mass index, insulin resistance, and inflammation. Gynecol Endocrinol 2015; 31 (09) 720-724
- 19 Glintborg D, Sidelmann JJ, Altinok ML, Mumm H, Andersen M. Increased thrombin generation in women with polycystic ovary syndrome: a pilot study on the effect of metformin and oral contraceptives. Metabolism 2015; 64 (10) 1272-1278
- 20 Rasmussen JJ, Selmer C, Østergren PB. , et al. Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case–control study. PLoS One 2016; 11 (08) e0161208
- 21 Rasmussen JJ, Schou M, Selmer C. , et al. Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids. Clin Endocrinol (Oxf) 2017; 87 (03) 249-256
- 22 Rasmussen JJ, Schou M, Madsen PL. , et al. Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma?. J Hypertens 2017; 36 (02) 277-285
- 23 Bhasin S, Woodhouse L, Casaburi R. , et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281 (06) E1172-E1181
- 24 Hemker HC, Giesen P, Al Dieri R. , et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33 (01) 4-15
- 25 Duchemin J, Pan-Petesch B, Arnaud B, Blouch MT, Abgrall JF. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost 2008; 99 (04) 767-773
- 26 Anderson RA, Ludlam CA, Wu FC. Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost 1995; 74 (02) 693-697
- 27 Brady JN, Notley C, Cameron C, Lillicrap D. Androgen effects on factor IX expression: in-vitro and in-vivo studies in mice. Br J Haematol 1998; 101 (02) 273-279
- 28 Naderi A. Coagulation factor VII is regulated by androgen receptor in breast cancer. Exp Cell Res 2015; 331 (01) 239-250
- 29 Brodin E, Appelbom H, Osterud B, Hilden I, Petersen LC, Hansen JB. Regulation of thrombin generation by TFPI in plasma without and with heparin. Transl Res 2009; 153 (03) 124-131
- 30 Agledahl I, Brodin E, Svartberg J, Hansen JB. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels. Thromb Haemost 2009; 101 (03) 471-477
- 31 van Kesteren PJ, Kooistra T, Lansink M. , et al. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb Haemost 1998; 79 (05) 1029-1033
- 32 Jin H, Lin J, Fu L. , et al. Physiological testosterone stimulates tissue plasminogen activator and tissue factor pathway inhibitor and inhibits plasminogen activator inhibitor type 1 release in endothelial cells. Biochem Cell Biol 2007; 85 (02) 246-251
- 33 Jin H, Wang DY, Mei YF. , et al. Mitogen-activated protein kinases pathway is involved in physiological testosterone-induced tissue factor pathway inhibitor expression in endothelial cells. Blood Coagul Fibrinolysis 2010; 21 (05) 420-424
- 34 Preston FE, Burakowski BK, Porter NR, Malia RG. The fibrinolytic response to stanozolol in normal subjects. Thromb Res 1981; 22 (5-6): 543-551
- 35 Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 2016; 62 (05) 699-707
- 36 Sidelmann JJ, Kluft C, Krug AH, Winkler U, Jespersen J, Gram JB. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women. Thromb Haemost 2017; 117 (04) 700-705
- 37 Martinez C, Suissa S, Rietbrock S. , et al. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ 2016; 355: i5968
- 38 Berezovskaya G, Smirnova O, Malev E. , et al. Thrombin generation test for evaluation of antiplatelet treatment in patients with coronary artery disease after percutaneous coronary intervention. Platelets 2017; Apr. 4: 1-7